United European gastroenterology journal · 2021
Development and validation of a prognostic score for long-term transplant-free survival in autoimmune hepatitis type 1.
СтатьяМногоцентровое исследованиеПоддержка исследования: вне правительства СШАВалидационное исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Biewenga Maaike, Verhelst Xavier P D M J, Baven-Pronk Martine A M C, Putter Hein, van den Berg Aad P, van Nieuwkerk Karin C M J, van Buuren Henk R, Bouma Gerd, de Boer Ynte S, Simoen Cedric, Colle Isabelle, Schouten Jeoffrey, Sermon Filip, van Steenkiste Christophe, van Vlierberghe Hans, van der Meer Adriaan J, Nevens Frederik, van Hoek Bart, Dutch Autoimmune Hepatitis Study Group
Аннотация
BACKGROUND: No prognostic score is currently available for long-term survival in autoimmune hepatitis (AIH) patients.
OBJECTIVE: The aim of this study was to develop and validate such a prognostic score for AIH patients at diagnosis.
METHODS: The prognostic score was developed using uni- & multivariate Cox regression in a 4-center Dutch cohort and validated in an independent 6-center Belgian cohort.
RESULTS: In the derivation cohort of 396 patients 19 liver transplantations (LTs) and 51 deaths occurred (median follow-up 118 months; interquartile range 60-202 months). In multivariate analysis age (hazard ratio [HR] 1.045; p < 0.001), non-caucasian ethnicity (HR 1.897; p = 0.045), cirrhosis (HR 3.266; p < 0.001) and alanine aminotransferase level (HR 0.725; p = 0.003) were significant independent predictors for mortality or LT (C-statistic 0.827; 95% CI 0.790-0.864). In the validation cohort of 408 patients death or LT occurred in 78 patients during a median follow-up of 74 months (interquartile range: 25-142 months). Predicted 5-year event rate did not differ from observed event rate (high risk group 21.5% vs. 15.7% (95% CI: 6.3%-24.2%); moderate risk group 5.8% versus 4.3% (95% CI: 0.0%-9.1%); low risk group 1.9% versus 5.4% (95% CI: 0.0%-11.4%); C-statistic 0.744 [95% CI 0.644-0.844]).
CONCLUSIONS: A Dutch-Belgian prognostic score for long-term transplant-free survival in AIH patients at diagnosis was developed and validated.
OBJECTIVE: The aim of this study was to develop and validate such a prognostic score for AIH patients at diagnosis.
METHODS: The prognostic score was developed using uni- & multivariate Cox regression in a 4-center Dutch cohort and validated in an independent 6-center Belgian cohort.
RESULTS: In the derivation cohort of 396 patients 19 liver transplantations (LTs) and 51 deaths occurred (median follow-up 118 months; interquartile range 60-202 months). In multivariate analysis age (hazard ratio [HR] 1.045; p < 0.001), non-caucasian ethnicity (HR 1.897; p = 0.045), cirrhosis (HR 3.266; p < 0.001) and alanine aminotransferase level (HR 0.725; p = 0.003) were significant independent predictors for mortality or LT (C-statistic 0.827; 95% CI 0.790-0.864). In the validation cohort of 408 patients death or LT occurred in 78 patients during a median follow-up of 74 months (interquartile range: 25-142 months). Predicted 5-year event rate did not differ from observed event rate (high risk group 21.5% vs. 15.7% (95% CI: 6.3%-24.2%); moderate risk group 5.8% versus 4.3% (95% CI: 0.0%-9.1%); low risk group 1.9% versus 5.4% (95% CI: 0.0%-11.4%); C-statistic 0.744 [95% CI 0.644-0.844]).
CONCLUSIONS: A Dutch-Belgian prognostic score for long-term transplant-free survival in AIH patients at diagnosis was developed and validated.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overBelgiumChildChild, PreschoolCohort StudiesDecision Support TechniquesDisease ProgressionDisease-Free SurvivalFemaleHepatitis, AutoimmuneHumansLiver CirrhosisLiver TransplantationMaleMiddle AgedMultivariate AnalysisNetherlandsPrognosisProportional Hazards ModelsReproducibility of ResultsRisk AssessmentRisk FactorsTime FactorsYoung Adult